vs
Side-by-side financial comparison of KKR Real Estate Finance Trust Inc. (KREF) and ZEVRA THERAPEUTICS, INC. (ZVRA). Click either name above to swap in a different company.
ZEVRA THERAPEUTICS, INC. is the larger business by last-quarter revenue ($34.1M vs $25.8M, roughly 1.3× KKR Real Estate Finance Trust Inc.). On growth, ZEVRA THERAPEUTICS, INC. posted the faster year-over-year revenue change (183.4% vs -26.6%). Over the past eight quarters, ZEVRA THERAPEUTICS, INC.'s revenue compounded faster (215.7% CAGR vs -18.8%).
KKR Real Estate Finance Trust Inc. is a specialized real estate finance firm sponsored by global investment firm KKR. It primarily originates, acquires, and manages a portfolio of senior secured commercial real estate loans, mostly backed by high-quality institutional commercial properties across the United States, delivering stable risk-adjusted returns to investors via interest income from its diversified assets.
Zevra Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with rare under-treated orphan diseases, with a primary focus on central nervous system and metabolic rare disorder segments. Its main target markets are North America and the European Union.
KREF vs ZVRA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.8M | $34.1M |
| Net Profit | $-26.2M | — |
| Gross Margin | — | — |
| Operating Margin | -105.1% | 27.3% |
| Net Margin | -101.7% | — |
| Revenue YoY | -26.6% | 183.4% |
| Net Profit YoY | -229.6% | — |
| EPS (diluted) | $-0.49 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.8M | $34.1M | ||
| Q3 25 | $25.3M | $26.1M | ||
| Q2 25 | $30.2M | $25.9M | ||
| Q1 25 | $31.3M | $20.4M | ||
| Q4 24 | $35.1M | $12.0M | ||
| Q3 24 | $37.0M | $3.7M | ||
| Q2 24 | $40.4M | $4.4M | ||
| Q1 24 | $39.1M | $3.4M |
| Q4 25 | $-26.2M | — | ||
| Q3 25 | $13.8M | $-544.0K | ||
| Q2 25 | $-29.7M | $74.7M | ||
| Q1 25 | $-4.9M | $-3.1M | ||
| Q4 24 | $20.3M | — | ||
| Q3 24 | $-7.4M | $-33.2M | ||
| Q2 24 | $25.8M | $-19.9M | ||
| Q1 24 | $-3.1M | $-16.6M |
| Q4 25 | -105.1% | 27.3% | ||
| Q3 25 | 50.4% | 15.9% | ||
| Q2 25 | -101.3% | -274.5% | ||
| Q1 25 | -18.3% | -26.3% | ||
| Q4 24 | 55.8% | -128.0% | ||
| Q3 24 | -19.6% | -739.0% | ||
| Q2 24 | 63.3% | -534.8% | ||
| Q1 24 | -8.7% | -598.1% |
| Q4 25 | -101.7% | — | ||
| Q3 25 | 54.4% | -2.1% | ||
| Q2 25 | -98.5% | 288.7% | ||
| Q1 25 | -15.5% | -15.2% | ||
| Q4 24 | 57.7% | — | ||
| Q3 24 | -20.0% | -899.2% | ||
| Q2 24 | 63.9% | -447.9% | ||
| Q1 24 | -7.9% | -485.3% |
| Q4 25 | $-0.49 | — | ||
| Q3 25 | $0.12 | $-0.01 | ||
| Q2 25 | $-0.53 | $1.21 | ||
| Q1 25 | $-0.15 | — | ||
| Q4 24 | $0.22 | — | ||
| Q3 24 | $-0.19 | $-0.69 | ||
| Q2 24 | $0.29 | $-0.48 | ||
| Q1 24 | $-0.13 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $84.6M | $62.4M |
| Total DebtLower is stronger | — | $61.9M |
| Stockholders' EquityBook value | $1.2B | $154.7M |
| Total Assets | $6.5B | $284.7M |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $84.6M | $62.4M | ||
| Q3 25 | $204.1M | $54.4M | ||
| Q2 25 | $107.7M | $47.7M | ||
| Q1 25 | $106.4M | $37.3M | ||
| Q4 24 | $104.9M | $33.8M | ||
| Q3 24 | $108.8M | $54.0M | ||
| Q2 24 | $107.2M | $39.3M | ||
| Q1 24 | $106.5M | $42.8M |
| Q4 25 | — | $61.9M | ||
| Q3 25 | — | $61.3M | ||
| Q2 25 | — | $60.7M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $59.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $154.7M | ||
| Q3 25 | $1.2B | $133.2M | ||
| Q2 25 | $1.2B | $117.2M | ||
| Q1 25 | $1.3B | $41.0M | ||
| Q4 24 | $1.3B | $39.7M | ||
| Q3 24 | $1.4B | $69.8M | ||
| Q2 24 | $1.4B | $32.5M | ||
| Q1 24 | $1.4B | $48.8M |
| Q4 25 | $6.5B | $284.7M | ||
| Q3 25 | $6.5B | $270.1M | ||
| Q2 25 | $6.8B | $256.3M | ||
| Q1 25 | $6.6B | $172.7M | ||
| Q4 24 | $6.4B | $178.1M | ||
| Q3 24 | $6.8B | $191.6M | ||
| Q2 24 | $7.1B | $144.4M | ||
| Q1 24 | $7.3B | $151.3M |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.50× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $72.3M | $5.5M |
| Free Cash FlowOCF − Capex | — | $5.5M |
| FCF MarginFCF / Revenue | — | 16.1% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $72.3M | $5.5M | ||
| Q3 25 | $18.5M | $4.7M | ||
| Q2 25 | $21.1M | $-3.6M | ||
| Q1 25 | $15.9M | $-8.2M | ||
| Q4 24 | $132.6M | $-16.3M | ||
| Q3 24 | $49.1M | $-18.1M | ||
| Q2 24 | $30.6M | $-19.1M | ||
| Q1 24 | $34.5M | $-16.2M |
| Q4 25 | — | $5.5M | ||
| Q3 25 | — | $4.2M | ||
| Q2 25 | — | $-3.8M | ||
| Q1 25 | — | $-8.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 16.1% | ||
| Q3 25 | — | 15.9% | ||
| Q2 25 | — | -14.7% | ||
| Q1 25 | — | -40.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 1.34× | — | ||
| Q2 25 | — | -0.05× | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.54× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.19× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KREF
Segment breakdown not available.
ZVRA
| MIPLYFFA | $26.4M | 77% |
| Arimoclomol Purchase Agreement | $5.7M | 17% |
| Other | $2.0M | 6% |
